Leuprolide Acetate Articles
Canada’s QLT sells US unit to TOLMAR for up to $230 million; aims to concentrate to ocular therapy
2 October 2009
Deeper loss but bright future for MediGene
17 April 2009
QLT closes Aczone deal with Allergan
21 July 2008
Repros' Proellex sees strong Ph II data
21 July 2008
Abbott reports 35% rise in earnings
28 April 2008
QLT sees 3rd-qtr profit, but job cuts planned
5 November 2007
QLT's 6-month Eligard cleared in EU
10 September 2007
QLT's 1st-qtr 2007 EPS falls 54% on Visudyne
7 May 2007
QLT
11 December 2006
Voyager sees positive data from Ph II AD trial
24 July 2006
Sosei to cut back jobs and reduce pipeline
3 July 2006
Medigene in profit
22 May 2006
Voyager's completes trial of potential AD drug
15 May 2006
Enrollment continues in Voyager's Ph III AD trial
24 April 2006
Stock Commentary - Europe - week to Jan 23
30 January 2006
Astellas sets up subsidiary in Spain
27 June 2005
Sosei files MAA for cancer drug SOT-375
7 March 2005
MediGene posts better than forecast 2004 results
21 February 2005
MediGene posts better than forecast 2004 results
21 February 2005
Voyager-Durect Alzheimer therapy enters Phase I
14 February 2005
FDA appro for QLT's Eligard 45mg six-month formulation
20 December 2004
Sosei looks to sales of 21B yen in 2010
13 December 2004
Atrix releases news on Eligard in Canada
15 March 2004
Atrix files for new Eligard formulation
1 March 2004
MediGene reduces losses for 2003
16 February 2004
Three-month Eligard cleared in Germany
9 February 2004
MediGene finds partner for Eligard
26 January 2004
Atrix' Eligard approved in Australia; co-promotion deal in Japan
22 December 2003
MediGene/Atrix' leuprolide gets German approval
8 December 2003
Eligard products approved in Canada
17 November 2003
Atrix to miss targets on higher costs
29 September 2003
German regulators clear Atrix facility
2 June 2003
4-month Eligard cleared in USA
24 February 2003
53.7% US sales leap boosts Sanofi-Synthelabo
27 January 2003
Atrix licenses Eligard to Japan's Sosei
13 January 2003
Atrix submits INDA for additional Eligard dose
12 August 2002
Eligard FDA-approved
5 August 2002
Atrix gets first payment for Eligard launch
22 July 2002
Sanofi-Synthelabo launches Eligard in USA
3 June 2002
Sanofi-Synthelabo 2001 EPS leap 44%
25 February 2002
Bayer realigns US pharma sales force
11 February 2002
FDA approves Atrix' prostate cancer depot
28 January 2002
Atrix submits NDA to FDA for Leuprogel three-month product
28 September 2001
Atrix/Faulding enter deal for Leuprogel Depot
13 August 2001
Atrix to file for 3-month Leuprogel in USA
11 July 2001
Positive Ph III data for Praecis' abarelix
6 June 2001
Tokyo pharma stock market - week to April 23
25 April 2001
US pharma, doctors "kickbacks" warning
25 April 2001
Atrix/MediGene sign Leuprogel deal
9 April 2001
Atrix files for Leuprogel depot in USA
29 March 2001
Doctor, "Co X" accused over Medicare scam
22 February 2001
Stock Commentary - Tokyo
22 February 2001
Atrix plans to file for prostate cancer drug
7 December 2000
Pfizer's Steere to retire as CEO at end of 2000
11 August 2000
Bayer to market Alza's new Viadur implant in the USA
6 April 2000
Alza's Viadur approved for prostate cancer
8 March 2000
Atrix' Atrigel shows promise in Phase III
21 January 2000
Recent developments in drug delivery - by Mark Greener
19 January 2000
Abbott Laboratories and Alza Corp call off $7.3 billion merger
17 December 1999
Atrix poised for long-term growth in drug delivery
16 July 1999
Increases In Sales And Earnings At Abbott
15 October 1997
TAP Holdings' Lupron Depot Approved In USA
23 July 1997
Lupron Receives Additional Indication
10 April 1995
EISAI'S SALES AHEAD IN FLAT JAPANESE SECTOR
6 June 1994
NEW INDICATION FOR LUPRON DEPOT-PED
10 May 1993
Showing 1-78 of 78 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
